Want to see SE:IRLAB.A full AI Analyst Report?
Top Page
IRLAB Therapeutics AB Class A
(IRLAB.A)
Select Model
Select Model
Rating:52Neutral
Price Target:
kr1.50
▼(-25.37% Downside)
Action:Reiterated
Date:08/28/26
The score is held back primarily by weak financial performance (deep losses, contracting revenue, and ongoing cash burn), partially offset by a de-risked balance sheet. Technicals are a near-term positive with the stock trading above key moving averages and positive MACD, but valuation remains unattractive/unclear due to negative earnings and no dividend yield data.
Positive Factors
Improved balance-sheet resilience
Lower leverage and roughly 97M of equity provide a stronger financial cushion than in prior years. This reduces balance-sheet risk and may give IRLAB more flexibility to fund development while it remains pre-commercial.
Negative Factors
Persistent operating cash burn
Sustained negative operating and free cash flow means the business is not yet self-funding. Continued cash consumption can require additional financing, constrain development priorities, and increase dilution or funding risk before commercial revenue emerges.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved balance-sheet resilience
Lower leverage and roughly 97M of equity provide a stronger financial cushion than in prior years. This reduces balance-sheet risk and may give IRLAB more flexibility to fund development while it remains pre-commercial.
Read all positive factors
IRLAB Therapeutics AB Class A (IRLAB.A) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr256.08M
Dividend YieldN/A
Average Volume (3M)1.49M
Price to Earnings (P/E)―
Beta (1Y)0.46
Revenue Growth4.74%
EPS Growth66.33%
CountrySE
Employees31
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.65
Shares Outstanding148,632,140
10 Day Avg. Volume1,511,562
30 Day Avg. Volume1,488,908
Financial Highlights & Ratios
PEG Ratio-0.48
Price to Book (P/B)4.30
Price to Sales (P/S)2.30
P/FCF Ratio-2.39
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-2.57
Revenue Forecast (FY)kr102.00M
IRLAB Therapeutics AB Class A Business Overview & Revenue Model
Company Description
IRLAB Therapeutics AB (publ) is a pharmaceutical company committed to developing treatments for Parkinson's disease. Its clinical pipeline features Mesdopetam, currently progressing through phase IIb/III studies to address dyskinesia, and Pirepema...
How the Company Makes Money
IRLAB Therapeutics primarily generates revenue through collaboration and partnering arrangements for its drug candidates, which can include upfront payments, research funding, development and regulatory milestone payments, and royalties on future ...
IRLAB Therapeutics AB Class A Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
54
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 79.33M | 57.46M | 94.63M | 5.68M | 61.14M | 207.78M |
| Gross Profit | -46.31M | -92.35M | -92.42M | -122.73M | -111.23M | 168.69M |
| EBITDA | -40.55M | -88.03M | -68.07M | -173.32M | -109.13M | 55.79M |
| Net Income | -53.84M | -110.01M | -83.13M | -177.84M | -114.20M | 51.78M |
Balance Sheet | ||||||
| Total Assets | 182.37M | 138.21M | 136.21M | 177.12M | 323.56M | 472.45M |
| Cash, Cash Equivalents and Short-Term Investments | 34.22M | 81.86M | 66.92M | 111.31M | 252.78M | 401.90M |
| Total Debt | 24.20M | 29.95M | 60.42M | 27.57M | 3.98M | 6.60M |
| Total Liabilities | 85.24M | 107.49M | 103.58M | 61.36M | 32.72M | 72.97M |
| Stockholders Equity | 97.13M | 30.72M | 32.63M | 115.76M | 290.83M | 399.48M |
Cash Flow | ||||||
| Free Cash Flow | -61.05M | -55.22M | -65.79M | -165.14M | -145.99M | 127.93M |
| Operating Cash Flow | -61.05M | -55.22M | -65.59M | -164.85M | -142.61M | 128.64M |
| Investing Cash Flow | 0.00 | 0.00 | -199.00K | -293.00K | -3.38M | -708.00K |
| Financing Cash Flow | 42.65M | 73.41M | 21.40M | 23.68M | -3.13M | -3.04M |
IRLAB Therapeutics AB Class A Technical Analysis
Positive
2.01
Price Trends
1.46
Positive
1.38
Positive
1.58
Positive
Market Momentum
0.09
Positive
62.55
Neutral
52.93
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:IRLAB.A, the sentiment is Positive. The current price of 2.01 is above the 20-day moving average (MA) of 1.68, above the 50-day MA of 1.46, and above the 200-day MA of 1.58, indicating a bullish trend. The MACD of 0.09 indicates Positive momentum. The RSI at 62.55 is Neutral, neither overbought nor oversold. The STOCH value of 52.93 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:IRLAB.A.
IRLAB Therapeutics AB Class A Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | kr30.72B | 280.67 | 5.18% | 0.69% | -46.09% | -90.13% | |
64 Neutral | kr1.64B | 8.81 | 29.71% | ― | 24.98% | -31.44% | |
52 Neutral | kr256.08M | -2.63 | -97.06% | ― | 4.74% | 66.33% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | kr1.12B | 54.79 | 65.99% | ― | ― | ― | |
49 Neutral | kr930.08M | -8.88 | -58.12% | ― | ― | 1.42% | |
45 Neutral | kr172.24M | -3.89 | -17.52% | ― | -100.00% | 20.96% |
* Healthcare Sector Average
SE:IRLAB.A
IRLAB Therapeutics AB Class A
1.71
-0.93
-35.15%
SE:ALZ
Alzinova AB
0.82
-0.60
-42.21%
SE:ALZCUR
AlzeCure Pharma AB
8.18
5.09
164.64%
SE:BIOA.B
BioArctic AB Class B
334.00
45.51
15.78%
SE:SYNACT
SynAct Pharma AB
17.50
-1.52
-7.99%
SE:SANION
Saniona AB
11.81
-1.45
-10.94%
IRLAB Therapeutics AB Class A Corporate Events
IRLAB strengthens Parkinson’s pipeline and finances in Q2 2026
Aug 26, 2026
IRLAB reported second-quarter 2026 net sales of SEK 6.4 million, down from SEK 19.5 million a year earlier, and an operating loss of SEK 16.7 million, while earnings per share improved to a loss of SEK 0.23 versus SEK 0.62. The company’s rig...
IRLAB to Webcast Q2 2026 Interim Report as Parkinson’s Pipeline Advances
Aug 20, 2026
IRLAB Therapeutics AB, a Gothenburg-based biotech specializing in novel Parkinson’s disease therapies, is advancing a diversified clinical and preclinical pipeline built on its proprietary systems biology-based research platform. With multip...
WHO Grants INN Name to IRLAB’s Apathy Drug Candidate Linepemat
Aug 19, 2026
IRLAB Therapeutics AB, a Gothenburg-based biopharmaceutical company specializing in Parkinson’s disease and other neurodegenerative disorders, is building a diversified pipeline of small-molecule drug candidates addressing motor complication...
IRLAB Updates Share Capital After Rights Issue to Support Parkinson’s Pipeline
Jul 31, 2026
IRLAB Therapeutics AB is a Swedish biopharmaceutical company focused on discovering and developing transformative treatments for all stages of Parkinson’s disease and related neurodegenerative disorders. Originating from Nobel Laureate Arvid...
IRLAB Completes Registration of Rights Issue and Converts Interim Shares
Jul 10, 2026
IRLAB Therapeutics AB has completed the registration of its rights issue of ordinary shares of series A with the Swedish Companies Registration Office, enabling the conversion of paid subscribed shares into listed ordinary shares on Nasdaq Stockho...
IRLAB Therapeutics AGM Confirms No Dividend and New Director Incentives
Jun 30, 2026
IRLAB Therapeutics AB held its Annual General Meeting in Gothenburg, where shareholders approved the 2025 income statement and balance sheet, confirmed that SEK 342,105,791 will be carried forward, and decided that no dividend will be paid for the...
IRLAB Raises SEK 76.5 Million in Oversubscribed Rights and Overallotment Issues
Jun 29, 2026
IRLAB Therapeutics has completed a rights issue of series A ordinary shares that was oversubscribed, raising approximately SEK 68 million before costs, with 58.5 percent subscribed using subscription rights and additional strong demand without rig...
IRLAB’s Mesdopetam Shows Robust Phase II Efficacy in Integrated Analysis Ahead of Partnering Talks
Jun 16, 2026
IRLAB Therapeutics will present an integrated analysis of clinical data for mesdopetam, its most advanced Parkinson’s candidate for levodopa-induced dyskinesia, at the StanCon 2026 conference in Uppsala. The study pools data from randomized,...
IRLAB launches largely underwritten SEK 68 million rights issue
Jun 11, 2026
IRLAB Therapeutics AB has launched the subscription period for a rights issue of up to approximately SEK 68 million in new series A ordinary shares, giving existing shareholders preferential rights to participate. The offer, priced at SEK 1.20 per...
IRLAB Secures Strong Backing for SEK 68 Million Rights Issue
Jun 5, 2026
IRLAB Therapeutics has received shareholder approval to proceed with a rights issue of series A ordinary shares of up to approximately SEK 68 million, alongside an overallotment issue of up to about SEK 33.8 million, both backed by amendments to i...
IRLAB Shareholders Approve New Share Issues and Elect Two New Board Members
Jun 5, 2026
IRLAB Therapeutics AB reported that its Extraordinary General Meeting approved new issues of series A shares, both with and without preferential rights for existing shareholders, alongside amendments to its articles of association to adjust share ...
IRLAB to Showcase Parkinson’s Pipeline at Stockholm Investor Event
Jun 3, 2026
IRLAB Therapeutics AB, a Sweden-based biopharmaceutical developer of novel therapies for Parkinson’s disease and other neurodegenerative conditions, is advancing multiple drug candidates through clinical and preclinical stages, including Mes...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.